Inhibition of amyloid formation: A strategy to delay the onset of Alzheimer's disease

Current Opinion in Chemical Biology

Volumn 1, Issue 2, 1997, Pages 260-267

  Lansbury Jr , Peter T ^a  

^a Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; METABOLISM; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; HUMANS; SENILE PLAQUES;

EID: 0031197194     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(97)80018-X     Document Type: Article

References (57)

1. Lansbury PT Jr: A reductionist view of Alzheimer's disease. Accounts Chem Res 1996, 29:317-321.
2. Selkoe DJ: Alzheimer's disease: genotypes, phenotype, and treatments. Science 1997, 275:630-631.
3. Siman R, Scott RW: Strategies to alter the progression of Alzheimer's disease. Curr Opin Biotechnol 1996, 7:601-607.
4. Cummings BJ, Pike CJ, Shankle R, Cotman CW: β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 1996, 17:921-947. There has been considerable debate regarding the issue of which aspect of the AD pathology correlates most closely with cognitive deficit. Not surprisingly, the number of synapses at time of death strongly correlates [7], This paper concludes that, among features related to amyloid plaques and NFTs, the amount of deposited Aβ (both diffuse and neuritic plaque) correlates most strongly. This correlation does not speak to etiology, since the pathway from the root abnormality to neuronal death is expected to be complex and dependent on the individual. Several commentaries from experts in the field are included.
5. Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR: Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. JAMA 1996, 275:528-532. A group of 93 nuns between the ages of 75 and 93 were analyzed for signs of cognitive deficits ('probable AD'). Fifty-year-old writing samples from these nuns were independently scored for idea density and grammatical complexity. The incidence of probable AD was significantly greater in the group of nuns whose writing samples scored lower with respect to these parameters. This correlation did not seem to result from the ability of the more intelligent group to compensate for neuronal loss and mask symptoms: the extent of AD pathology also inversely correlated with the complexity of writing. This preliminary study suggests either that an endogenous factor which may increase brain plasticity may also inhibit the deposition of amyloid or that overproduction of Aβ and/or its increased deposition may begin very early in life.
6. Terry RDL: The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol 1996, 55:1023-1025.
7. Schenk DB, Rydel RE, May P, Little S, Panetta J, Lieberburg I, Sinha S: Therapeutic approaches related to amyloid-β peptide and Alzheimer's disease. J Med Chem 1995, 38:4141-4154.
8. Levitan D, Greenwald I: Facilitation of lin-12-mediated signaling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 1995, 377:351-354.
9. Weidemann A, Paliga K, Durrwang U, Czech C, Evin G, Masters CL, Beyreuther K: Formation of stable complexes between two Alzheimer's disease gene products: presenilin-2 and β-amyloid precursor protein. Nat Med 1997, 3:328-332.
10. •], showing that elevation of Aβ1-42 is not the only mechanism to accelerate amyloid deposition.
11. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A et al.: Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β protein in both transfected cells and transgenic mice. Nat Med 1997, 3:1-6.
12. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D et al.: Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/Aβ1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013.
13. Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D et al.: Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996, 383:710-713.
14. Jarrett JT, Berger EP, Lansbury PT Jr: The carboxy terminus of β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993, 32:4693-4697.
15. Lemere CA, Lopera F, Kosik K, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L et al.: The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology. Nat Med 1996, 2:1146-1150. The pathogenic role of Aβ1-42 was proposed in [14], based on biophysical studies. This paper reports the first ex vivo human studies in support of that hypothesis. The brains of early-onset AD patients from a Colombian family bearing a PS1 mutation contain sugnificantly increased amounts of Aβ1-42 deposition as compared to late-onset (sporadic) AD brains. However, the levels of deposited Aβ1-40 are indistinguishable between the two groups.
16. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, Scartezzini P, Bertoloni S, Mann DMA, Tabaton M, Gambetti P: Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 1996, 2:93-95. The brains of DS patients were shown îo contain considerably higher concentrations of 'soluble' Aβ1-42 than age-matched controls, even in young patients in whom amyloid plaques were not present.
17. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ: Sequence of deposition of heterogeneous amyloid β-peptides and apoE in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 1996, 3:16-32. Diffuse Aβ1-42 deposits were present in young DS brains, long before substantial Aβ1-40 deposition was detected and AD pathology and possible symptoms occurred.
18. Lippa, CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD: Apoplipoprotein E-ε2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 1997, 48:515-519.
19. Greenberg SM, Rebeck W, Vonsattel JPG, Gomez-Isla T, Hyman BT: Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995, 38:254-259.
20. Hyman BT, West HL, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, Stanley HE: Quantitative analysis of senile plaques in Alzheimer's disease: observation of log-normal distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). Proc Natl Acad Sci USA 1995, 92:3586-3590.
21. Gearing M, Mori H, Mirra SS: Aβ peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 1996, 39:395-399. This paper reports that the apoE4 allele correlates with elevated Aβ1-40 deposition, whereas amounts of deposited Aβ1-42 are unchanged. This situation, which stands in contrast to the opposite observation in chromosome 14 FAD brains, emphasizes that apoE affects a different stage of the pathogenic pathway (Figure 1).
22. Nicoll JAR, Roberts GW, Graham DI: Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury. Nat Med 1995, 1:135-137. Head trauma increases the risk of developing AD later in life. The brains of head trauma patients who died soon after the accident were analyzed. About one third of patients were characterized by large amounts of diffuse amyloid deposits in the brain. In this study, it is demonstrated that, in a small sample, the amount of diffuse amyloid can be predicted by apoE genotype, with the apoE4 allele being overrepresented in the group of head trauma patients with extensive diffuse amyloid.
23. •] suggests that this may be the case.
24. Yankner BA: Mechanism of neuronal degeneration in Alzheimer's disease. Neuron 1996, 16:921-932.
25. Ghanta J, Shen C-L, Kiessling LL, Murphy RM: A strategy for designing inhibitors of β-amyloid toxicity. J Biol Chem 1996, 271:29525-29528.
26. Velazquez P, Cribbs DH, Poulos TL, Tenner AJ: Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat Med 1997, 3:77-79.
27. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Lokie JD: Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils. Nature 1996, 382:716-719.
28. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory defects, Aβ elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102. This mouse model, in contrast to the Games et al. model [29], is reported to show time-dependent progression of neurological symptoms (the amyloid load in the Games et al. mouse is much higher, so the progression of symptoms may have plateaued), but both models show no NFTs and no clear neuronal loss.
29. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995, 373:523-527.
30. Hsiao KK, Borchelt DR, Olson K, Johanssdottir R, Kitt C, Yunis W, Xu S, Eckman C, Younkin, S, Price D et al.: Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 15:1203-1218.
31. Muller U, Cristina N, Li Z, Wolfer DP, Lipp H, Rulicke T, Brandner S, Aguzzi A, Weissmann C: Behavioral and anatomical deficits in mice homozygous for a modified β-amyloid precursor protein gene. Cell 1994, 79:755-765.
32. Martin BL, Schrader-Fischer G, Busciglio J, Duke M, Paganetti P, Yankner BA: Intracellular accumulation of β-amyloid in cells expressing the Swedish mutant amyloid precursor protein. J Biol Chem 1995, 270:26727-26730.
33. Fuller SJ, Storey E, Li QX, Smith Al, Beyreuther K, Masters CL: Intracellular production of βA4 amyloid of Alzheimer's disease: modulation by phosphoramidon and lack of coupling to the secretion of the amyloid precursor protein. Biochemistry 1995, 34:8091-8098.
34. Turner RS, Suzuki N, Chyung, ASC, Younkin SG, Lee VMY: Amyloids β40 and β427 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem 1996, 271:8966-8970. The relative amounts of Aβ1-40 and Aβ1-42 secreted into the medium (ratio ≈20:1) differed significantly from the amount of trypsin-resistant Aβ, presumed to be intracellular (≈3:1). The authors suggest that Aβ1-42 is not generated via the secretory pathway.
35. Schrader-Fischer G, Staufenbiel M, Paganetti PA: Insertion of lysosomal targetting sequences to the amyloid precursor protein reduces secretion of βA4. J Neurochem 1997, 68:1571-1580.
36. Zhou Z, Liyanage U, Medina M, Ho C, Simmons AD, Lovett M, Kosik KS: Presenilin 1 interacts in brain with a novel member of the Armadillo family. Neuroreport 1997, 8:1489-1494. The yeast two-hybrid assay was utilized to discover proteins which interact with the cytoplasmic loop of PS1. The interacting protein was identified as δ-catenin, a brain-specific member of the catenin family. The catenins are homologous to the products of the Drosophila segment polarity gene Armadillo, a component of the Wingless signalling pathway. The implication is that the PS proteins may also be involved in development and that the partially elucidated pathways that control development may also play a role in AD; for example, the activity of PS1 could be modified by activation of a cell-surface receptor.
37. Citron M, Diehl TS, Capell A, Haas C, Teplow DB, Selkoe DJ: Inhibition of amyloid β-protein production in neural cells by the serine protease inhibitor AEBSF. Neuron 1996, 17:171-179.
38. Kalfki HW, Abramowski D, Swoboda R, Paganetti PA, Staufenbiel M: The carboxyl termini of β-amyloid peptides 1-40 and 1-42 are generated by distinct γ-secretase activities. J Biol Chem 1996, 271:28655-28659.
39. Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ: Evidence that the 42- and 40- amino acid forms of amyloid β protein are generated from the β-amyloid precursor protein by different protease activities. Proc Natl Acad Sci USA 1996, 93:13170-13175.
40. ••]. Only total Aβ was measured; therefore, the separate effects of each mutation on Aβ1-40 and Aβ1-42 production need to be determined, since it is not clear that Aβ1-40 and Aβ1-42 are produced by the same γ-secretase [39].
41. Tjernberg LO, Naslund J, Thyberg J, Gandy SE, Terenius L, Nordstedt C: Generation of Alzheimer amyloid β peptide through nonspecific proteolysis. J Biol Chem 1997, 272:1870-1875. This paper reports that the 100 amino acid carboxy-terminal fragment of APP polymerizes in vitro to form amyloid fibrils. This fragment, called C100, forms intracellular amyloid fibrils when overexpressed in COS cells [53]; the phenotype is 'rescued' by coexpression of apoE [48], These fibrils were treated with the nonspecific protease, proteinase K, to afford a protease-resistant fragment which is indistinguishable from synthetic Aβ1-40 on SDS-PAGE. Whether this cleavage product is Aβ1-40, Aβ1-42, another uncommon isoform (e.g. Aβ1-41), or a mixture of these was not determined, but is a critical question, since the authors propose that this in vitro proteolysis may mimic the biological mechanism used to generate Aβ. The phenomenon of a protein polymer being specifically cleaved by a sequence-nonspecific protease is precedented in the case of the scrapie-specific form of the prion protein (PrPSc), which is characterized by the fact that a specific amino-terminal sequence is cleaved by proteinase K. Another possibly related finding that is also reminiscent of the prion characteristics is the fact that Aβ1-42 fibrils can be internalized by cultured cells and induce abnormal stability in an APP fragment [54].
42. Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone MG, Garini P et al.: Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995, 92:2959-2963.
43. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA: Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1995, 2:143-148.
44. ••].
45. •]) which affect the early stages of amyloid formation, that is, nucleation, protofibril growth, and protofibril→fibril transition (Figure 3).
46. Wood SJ, Chan W, Wetzel R: Seeding of Aβ fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 1996, 35:12623-12628.
47. Wood SJ, MacKenzie L, Maleeff B, Hurle MR, Wetzel R: Selective inhibition of A-beta fibril formation. J Biol Chem 1996, 271:4086-4092.
48. Ohman T, Dang N, LeBoeuf RC, Furlong CE, Fukuchi K: Expression of apolipoprotein E inhibits the aggregation of the C-terminal fragments of β-amyloid precursor protein. Neurosci Lett 1996, 210:65-68.
49. •] and cell culture [48] studies, that apoE is an aggregation inhibitor.
50. Hoshi M, Takashima A, Murayama M, Yasutake K, Yoshida N, Ishiguri K, Hoshino T, Imahori K: Nontoxic amyloid β-peptide 1-42 suppresses acetylcholine synthesis. J Biol Chem 1997, 272:2038-2041.
51. Han H, Cho C-G, Lansbury PT Jr: Technetium complexes for the quantitation of brain amyloid. J Am Chem Soc 1996,118:4506-4507.
52. Maruyama K, Terakado K, Usami M, Yoshikawa K: Formation of amyloid-like fibrils in COS cells overexpressing part of the Alzheimer amyloid protein precursor. Nature 1990, 347:566-569.
53. Yang AJ, Knauer M, Burdick DA, Glabe C: Intracellular Aβ1-42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J Biol Chem 1995 270:14786-14792. This paper reports that Aβ1-42 fibrils can be internalized and induce abnormal stability in amyloidogenic fragments of APP.
54. Xia W, Zhang J, Koo EH, Selkoe DJ: Interaction between amyloid precursor protein and presenilins in mammalian cells: implications for the pathogenesis of Alzheimer's disease. Proc Natl Acad Sci USA 1997, in press. This paper reports that PS and APP interact in the endoplasmic reticulum of nontransfected cells.
55. Nalbantoglu J, Tirado-Santiago G, Lahnsaini A, Poirer J, Goncalves O, Verge G, Momoli F, Weiner SA, Massicotte G, Julien J-P, Shapiro ML: Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature 1997, 387:500-505.
56. Naiki H, Gejyo F, Nakakuki K: Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's disease β-amyloid fibril formation in vitro. Biochemistry 1997, 36:6243-6250.
57. Tagliavini F, McArthur RA, Cancianci B, Giaccone G, Porro M, Bugiani M, Lievens PM-J, Bugiani O, Peri E, Dall'Ara P et al.: Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 1997, 276:1119-1122.